Short interest for AEterna Zentaris gives investors a sense of the degree to which investors are betting on the decline of AEterna Zentaris's stock. Short interest data is updated every two weeks.

AEterna Zentaris Stock (NASDAQ:AEZS), Short Interest Report

AEterna Zentaris

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland which generates key revenue, Ireland, Denmark, and others.

Biotech

News

Penny Stocks

Health Care

General

AEZS

Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMZN

APLD

APLS

BRPM

BTBT

BTMD

CNTG

COIN

Core Scientific, Inc. - Class A Common Stock

CORZ

CPNG

CYCC

CYTO

DMTK

EOSE

FFHL

FFIE

GRRR

HCTI

HITI

HNST

HTGM

HUSA

IMTX

LIDR

LQDA

MARA

MRAI

MRTN

MSTR

MTCH

MYNA

NCNA

NFLX

NOTV

NVTA

NYXH

PXLW

RARE

SBNY

SDIG

SIDU

SKYX

STRY

SWVL

TBLT

TENX

THMO

TRKA

TUEM

TYDE

VERV

VOXX

WULF

Gainers


	Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.


Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday

Intraday Update

APRE

NYMX

XELA

Gainers


	Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.


This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday&#39;s Mid-Day Session

AEterna Zentaris Inc

AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported quarterly losses of $(4.74) per share which missed the analyst consensus estimate of $(0.81) by 485.19 percent. This is a 35.04 percent decrease over losses of $(3.51) per share from the same period last year.

Earnings

AEterna Zentaris Q1 2024 GAAP EPS $(4.74) Vs. $(3.51) Last Year

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Aeterna Zentaris Announced That It Has Filed Articles Of Amendment To Effect The Previously Announced Share Consolidation (or Reverse Stock Split) Of Its Issued And Outstanding Common Shares

AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported its Q4 earnings results on Wednesday, March 27, 2024 at 08:05 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
AEterna Zentaris missed estimated earnings by -20.0%, reporting an EPS of $-1.16 versus an estimate of $-0.97.
Revenue was down $2.36 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.24 which was followed by a 6.0% drop in the share price the next day.
Here's a look at AEterna Zentaris's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.61</td>
<td>-0.87</td>
<td>-1.07</td>
<td>-0.93</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.85</td>
<td>-0.52</td>
<td>-0.88</td>
<td>-0.84</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>2.30M</td>
<td>1.14M</td>
<td>900K</td>
<td>1.06M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3K</td>
<td>2.25M</td>
<td>2.13M</td>
<td>2.48M</td>
</tr>
</tbody>
</table>

To track all earnings releases for AEterna Zentaris <a href="https://www.benzinga.com/quote/AEZS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEterna Zentaris: Q4 Earnings Insights

AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.97) by 19.59 percent. The company reported $100.000 thousand in sales this quarter. This is a 95.98 percent decrease over sales of $2.485 million the same period last year.

Earnings Misses

AEterna Zentaris Q4 2023 GAAP EPS $(1.16) Misses $(0.97) Estimate, Sales $100.000K Down From $2.485M YoY

Aeterna Zentaris Completes Enrollment In Ongoing Pivotal DETECT-Trial For Diagnosis Of Childhood-Onset Growth Hormone Deficiency

Aeterna Zentaris, Ceapro Merger Approved by Securityholders At Special Meetings

CRPOF

Aeterna Zentaris Inks Pact With Ceapro To Create a Diversified Biopharmaceutical Company; Transaction Expected To Close In Q1 2024

Aeterna Zentaris Shares Were Halted Ahead Of News

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) with a Buy and lowers the price target from $28 to $15.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on AEterna Zentaris, Lowers Price Target to $15

AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.61) by 39.34 percent. This is a 21.43 percent decrease over losses of $(0.70) per share from the same period last year.

AEterna Zentaris Q3 EPS $(0.85) Misses $(0.61) Estimate

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) with a Buy and maintains $28 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on AEterna Zentaris, Maintains $28 Price Target

AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.87) by 40.23 percent. This is a 40.23 percent increase over losses of $(0.87) per share from the same period last year. The company reported quarterly sales of $2.25 million which beat the analyst consensus estimate of $1.14 million by 97.02 percent. This is a 1.11K percent increase over sales of $(222.00 thousand) the same period last year.

AEterna Zentaris Q2 EPS $(0.52) Beats $(0.87) Estimate, Sales $2.25M Beat $1.14M Estimate

<div>The company reports strong financial position with cash&nbsp;projected&nbsp;to fund operations and advancement of priority pipeline programs into&nbsp;2025.</div>

Aeterna Zentaris Says Encouraged By Progress Across All Of Its Active Development Programs

AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(1.07) by 17.76 percent. This is a 76 percent decrease over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $2.10 million which beat the analyst consensus estimate of $900.00 thousand by 133.33 percent. This is a 40.00 percent increase over sales of $1.50 million the same period last year.

AEterna Zentaris Q1 EPS $(0.88) Beats $(1.07) Estimate, Sales $2.10M Beat $900.00K Estimate

<ul>
<li>U.S.&nbsp;sales&nbsp;of&nbsp;Macrilen&reg;&nbsp;for adult use&nbsp;to be temporarily&nbsp;discontinued&nbsp;as&nbsp;of&nbsp;May 23, 2023,&nbsp;while&nbsp;DETECT trial&nbsp;continues in order to expand the&nbsp;opportunity&nbsp;for&nbsp;pediatric usage of&nbsp;Macrilen&reg; 
	&nbsp;</li>
<li>Sales and commercialization efforts continue to move forward in European Economic Area and UK under recent agreement with&nbsp;Pharmanovia 
	&nbsp;</li>
<li>United States Patent and Trademark Office (&quot;USPTO&quot;) has issued a Notice of Allowance for&nbsp;Aeterna&#39;s&nbsp;U.S. patent application related to&nbsp;use of&nbsp;macimorelin&nbsp;for&nbsp;Assessing Growth Hormone Deficiency in Children</li>
</ul>

Aeterna Zentaris Says US Sales Of Macrilen For Adult Use Will Be Temporarily Discontinued As Of May 23 Until Relaunch With An Alternate Commercialization Partner

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. has received final court approval to merge with Ceapro Inc. in a str...

Aeterna Zentaris Announces Merger Approval

The 48 rating InvestorsObserver gives to AEterna Zentaris Inc. (AEZS)  stock puts it near the top of the Healthcare sector.In addition to scoring higher than 72 percent of stocks in the Healthcare sector, AEZSâ€&#x2122;s 48 overall rating means the stock scores better than 48 of all stocks. AEZS has an Overall Score of 48. Find out

Is AEterna Zentaris Inc. (AEZS) Stock a Bad Value Thursday?

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. has announced a share consolidation which will reduce its current co...

Aeterna Zentaris Announces Share Consolidation

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. has announced the completion of its Share Consolidation on May 3, 20...

Aeterna Zentaris Completes Major Share Consolidation

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. has announced its Annual General and Special Meeting scheduled for J...

Aeterna Zentaris Sets Date for Virtual Shareholders Meeting

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. announced a strong cash position of $29.5 million at the end of the ...

Aeterna Zentaris: Strong Cash Reserve Amidst Upcoming Merger

Aeterna Zentaris GAAP EPS of -$4.74

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. has received consent from an independent accounting firm for the inc...

Aeterna Zentaris Gains Key Accounting Consent

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. reported a strong cash position of $29.5 million at the end of the f...

Aeterna Zentaris: Q1 Results and Upcoming Merger

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
AEterna Zentaris (NASDAQ:<a href="https://investorplace.com/stock-quotes/aezs-stock-quote/">AEZS</a>) just reported results for the first quarter of 2024.<ul><li>AEterna Zentaris reported earnings per share of -$4.74. This was below the analyst estimate for EPS of -81 cents.</li><li>The company reported revenue of $4,000.</li><li>This was 99.64% worse than the analyst estimate for revenue of $1.10 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/aezs-stock-earnings-aeterna-zentaris-for-q1-of-2024/">AEZS Stock Earnings: AEterna Zentaris Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AEZS Stock Earnings: AEterna Zentaris Misses EPS, Misses Revenue for Q1 2024

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, EVFM, AEZS, HOLI

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency